Open-label, multinational, multicenter phase IIIb/IV study of trastuzumab deruxtecan in patients with or without initial brain metastasis with previously treated HER2-positive advanced/metastatic breast cancer (DESTINY-Breast12).
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ASTRAZENECA AB
- Phase: III
- Execution start: 24/06/2022
- End of execution: 30/03/2024
- IP: ENCARNA GONZALEZ FLORES